Between 2015 and 2020, over 200 AI/ML-enabled medical devices received regulatory approval in the US and EU, with a strong focus on diagnostics and radiology.
Several of these innovations have already achieved reimbursement status, signaling a shift toward widespread adoption. One notable example covered by Puls Biznesu, one of Poland’s most prominent business publications, is BrainScan AI. This Gdańsk-based startup, led by Szymon Korzekwa, PhD, has developed an AI system to assist radiologists with the analysis of head CT scans. The tool has gained recognition and is currently being piloted in hospital settings.
These developments demonstrate how AI is transforming medical diagnostics—from niche prototypes to reimbursed, clinically meaningful solutions. At Axcellant, we continue to closely monitor these trends and explore how AI-powered tools can enhance imaging quality, trial efficiency, and ultimately, patient care.
Read more in the Puls Biznesu article (in Polish).
Clinical trials are often seen as a regulatory necessity, but for biotech and medtech startups, they can be much more.…
Axcellant participated in SNMMI’s 2025 Annual Meeting in New Orleans, where nearly 8,000 professionals in nuclear medicine and molecular imaging gathered…
Axcellant participated in the PET Symposium 2025, held in Turku, marking 50 years of PET radiochemistry at the Turku PET…
Copyright @ 2025 Axcellant